Stealth BioTherapeutics Corp is a clinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market treatments for illnesses arising from mitochondrial dysfunction. Its primary therapeutic candidate, Elamipretide, is currently progressing through multiple clinical stages: a Phase 3 trial for Barth Syndrome and replisome myopathies; a Phase 2/3 study for Duchenne cardiomyopathy; a Phase 2a investigation for Friedreich's ataxia; and Phase 2 trials for both dry age-related macular degeneration and Leber's hereditary optic neuropathy. The company's developmental pipeline further includes SBT-20, designed to address complications associated with diabetes, various renal and ocular conditions, and several neurodegenerative diseases such as Parkinson's, Alzheimer's, Huntington's, and ALS. Additionally, SBT-550 is being evaluated for rare neurological indications, while SBT-272, a peptidomimetic, is engineered to target and enhance mitochondrial function amidst oxidative stress. Established in 2006, Stealth BioTherapeutics Corp operates from its base in George Town, Cayman Islands.